Last updated on April 2018

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2)

Brief description of study

The co-primary objectives of the trial are to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 24 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on:

  • the frequency of pulmonary exacerbations;
  • the number of exacerbation-free days.

Clinical Study Identifier: NCT03460704

Contact Investigators or Research Sites near you

Start Over

Michela Meroni, MSc

EMED Centrum Us ug Medycznych
Rzeszów, Poland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.